UCB's Bimekizumab Could Struggle With Saturated Psoriasis Market

 
• By Lucie Ellis-Taitt

UCB's has reported strong Phase IIb data for its novel psoriasis therapy bimekizumab, but the drug is unlikely to launch before 2022 and is at risk of being redundant on a crowded market.

Elevator
Room For One More? UCB Must Find Space For Bimekizumab On Crowded Psoriasis Market • Source: Shutterstock

More from Clinical Trials

More from R&D